The confirmation of in vitro and in vivo experiments will help us conduct human trials to explore the combined effect of GLIS1 monoclonal antibodies with anti-PD1 or anti-CTLA-4 for future PCa treatment. This evidence concerns the gene CTLA4 and posterior cortical atrophy.